Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results

INTRODUCTION: Psoriasis is a debilitating, chronic inflammatory systemic disease affecting around 2% of the South American population. Biological therapies offer the possibility of long-term therapy with improved safety and efficacy. METHODS: We conducted a multicentre, open-label, single-arm, Phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Stengel, Fernando M, Petri, Valeria, Campbell, Gladys AM, Dorantes, Gladys Leon, López, Magdalina, Galimberti, Ricardo L, Valdez, Raúl P, de Arruda, Lucia F, Guerra, Mario Amaya, Chouela, Edgardo N, Licu, Daiana
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805872/
https://www.ncbi.nlm.nih.gov/pubmed/20098510
http://dx.doi.org/10.1111/j.1753-5174.2009.00024.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805872/
https://www.ncbi.nlm.nih.gov/pubmed/20098510
http://dx.doi.org/10.1111/j.1753-5174.2009.00024.x

Ejemplares similares